Multi-center evaluation of bionano optical genome mapping by cytogenetics thought leaders in the us leads to recommendation for bionano's saphyr to replace karyotyping as first-line test for detection and identification of structural and copy number variants in leukemia patients

San diego, nov. 11, 2020 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) announced the publication of a study led by cytogenetics experts from the nation's top clinical and cancer centers in which they recommended that optical genome mapping (ogm) using bionano's saphyr system be considered as a first-line test for detection and identification of clinically relevant structural variants and copy number variants in leukemias. the paper, published this week in medrxiv, describes detection and identification of structural variants and copy number variants in 100 patients with acute myeloid leukemia (aml). this study is the largest to-date in leukemia for bionano and the first published study from the united states comparing bionano's ogm to karyotyping, the current standard of care in leukemia testing.
BNGO Ratings Summary
BNGO Quant Ranking